Vaccinating policy

Topics Coronavirus | HIV Aids | Lockdown

The global pharmaceutical industry is racing to create a vaccine for coronavirus and the winning companies are certain to generate billions of dollars in revenue and wealth for shareholders. But the bigger concern once the vaccines enter the market is balancing intellectual property (IP) regimes with public health interests. In a recent article, Joseph Stiglitz, Arjun Jayadev, and Achal Prabhala have argued that current IP regimes, which enable Big Pharma monopolies to extract large profits from consumers, are unnecessary and they make the case for the benefits of “open science” in.....

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel
Key stories on are available to premium subscribers only.

Already a premium subscriber?

Subscribe to get an across device (Website, Mobile Web, Iphone, Ipad, and Android Phone applications) access to Premium content, Breaking News alerts, Industry Newsletters, Stock and Corporate news alerts, access to Archives and a lot more.